PPARG and Alzheimer disease: Although PPAR-γ stimulation affects microbiota, therapeutic effects of agonists most likely arise from the suppression of Th17 cells (17), epidermal keratinocyte growth (85), mast cell development and differentiation (86, 87), and IgE production (88), demonstrating several anti-inflammatory functions that may benefit AD patients (Figure 1).